Nuage Therapeutics

Biotechnology - Therapeutics and Diagnostics


Nuage Therapeutics’ (NTx) mission is to leverage biomolecular condensation and chemical biology to develop selective inhibitors of intrinsically disordered proteins involved in challenging indications representing unmet medical needs. NTx is a spin-off from the Institute for Research in Biomedicine (IRB) and ICREA that arises from the laboratory of Molecular Biophysics lead by Dr. Xavier Salvatella at the IRB.


NTx counts with the expertise of three scientific founders: Dr. Xavier Salvatella; Dr. Denes Hnisz, leader of the Precision Gene Control group at the Max Planck Institute for Molecular Genetics in Berlin; and Mateusz Biesaga, a biomedical engineer and PhD student responsible for assay development at NTx. NTx’s team also includes Dr. Georgina Sorrosal as Head of Operations and Dr. Jordina Guillén as Head of Research.

Contact person: Georgina Sorrosal

Location: Torre R - TR01B7